<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159884</url>
  </required_header>
  <id_info>
    <org_study_id>KH902-ST-CRP-2.0</org_study_id>
    <nct_id>NCT03159884</nct_id>
  </id_info>
  <brief_title>The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)</brief_title>
  <acronym>STAR</acronym>
  <official_title>The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Biotech Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Kanghong Biotech Co.,Ltd.</source>
  <brief_summary>
    <textblock>
      To assess the efficacy of intravitreal injection of 0.5 mg conbercept in patients with
      polypoidal choroidal vasculopathy (PCV) and explore the optimal route of administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Best Corrected Visual Acuity</measure>
    <time_frame>Baseline, 12th and 48th week</time_frame>
    <description>The investigators will use the ETARS Chart which is international standard to measure the vision ability of participants.Best corrected visual is the number of letters which the participants can read on the ETARS Chart ,all procedure should be done according to SOP.The BCVA of 12th week and 48th week will be compared with the base line（pre-treatment）.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Retinal Thickness (CRT)</measure>
    <time_frame>week 48</time_frame>
    <description>To observe pre- and posttreatment changes in CRT on OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Macular Retinal Thickness (MRT)</measure>
    <time_frame>week 48</time_frame>
    <description>To observe pre-and posttreatment changes on OCT;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume and Thickness of Retinal Pigment Epithelial Detachment (PED)</measure>
    <time_frame>week 48</time_frame>
    <description>To observe pre- and posttreatment changes in volume and thickness of PED on OCT;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area and Regression of Polypoidal Lesion</measure>
    <time_frame>week 48</time_frame>
    <description>To observe pre- and posttreatment changes in area and regression of polypoidal lesion on ICGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Retinal Hemorrhages</measure>
    <time_frame>week 48</time_frame>
    <description>To observe pre- and posttreatment changes in size of retinal hemorrhages on CFP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Branching Vascular Network</measure>
    <time_frame>week 48</time_frame>
    <description>To observe pre- and posttreatment changes in area of BVN on ICGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Administration</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Refers to the average frequency of administration for both groups of subjects during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and reactions</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ophthalmic examination</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Ophthalmic examination include corneal、vitreous body、anterior chamber、iris、retina、disc、Macular 、drusen、PED examination Investigator will check whether the parts above is normal. Measurement for summarizing the data : Number of patients with different conditions of each part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General symptoms and vital signs</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Number of participants with abnormal symptoms or vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as assessed by laboratory results</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Laboratory results include Blood routine 、Blood biochemistry、Coagulation function 、Urine routine 、Urinary pregnancy .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by other tests.</measure>
    <time_frame>up to 48 weeks.</time_frame>
    <description>Other tests indicated that which is not contained in the study done by the participants .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy (PCV)</condition>
  <arm_group>
    <arm_group_label>3+Q12W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the &quot;additional medication criteria&quot; in 12 weeks during treatment, additional injection can be given;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3+TAE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the &quot;treatment-extended dosing criteria&quot;. When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the &quot;extra dosing criteria&quot;.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept</intervention_name>
    <arm_group_label>3+Q12W</arm_group_label>
    <arm_group_label>3+TAE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who has signed an informed consent form and is inclined to be followed up
             within the time stipulated in the trial;

          -  Patient with wet AMD aged ≥ 45, of either sex;

          -  The eye of interest must meet the following requirements:

               1. BCVA is at least 19 and at most 83 alphabets (equivalent to a visual acuity of
                  20/25 to 20/400 for the Snellen Eye Chart);

               2. Patient has been diagnosed with active PCV on ICGA (confirmed by the third-party
                  radiodiagnosis center); The diagnostic criteria for &quot;active&quot; PCV on ICGA are as
                  follows: image indicates polypoid lesions as typical nodular high fluorescein
                  area (observed stereoscopically) and also depicts one of the following
                  angiographic findings: 1) nodular lesions surrounded by the weak halo; 2) nodular
                  lesions nourished by abnormal vascular beds; and 3) nodular pulsation on dynamic
                  ICGA;

               3. In case of the eye of interest complicated with subretinal hemorrhage or
                  hemorrhage under the pigment epithelium, the range of hemorrhage should not be
                  beyond the upper and lower vascular arcades in the macular area, and the total
                  thickness of the central fovea (i.e., the thickness between the apex of the
                  central fovea and the choriocapillary layer) is no more than 600 µm;

               4. Neither ocular media opacity nor miosis is noted to influence the fundus
                  examination.

          -  Subject with the BCVA of no less than 19 alphabets for his/her eye of non-interest
             (equivalent to a visual acuity of 20/400 for the Snellen Eye Chart).

        Note: Each subject in the study can include only one eye of interest; the eye of interest
        is determined by the researcher from a medical point of view if both eyes of the subject
        meet the inclusion criteria.

        Exclusion Criteria:

          -  Subfoveal fibrous tissues are present in the eye of interest on CFP and OCT;

          -  Researcher judges that existing or previous ocular diseases in the eye of interest
             influence the macular detection or the central visual acuity (CNV secondary to
             diseases other than AMD, diabetic retinopathy, uveitis, angioid streaks, pathologic
             myopia, retinal pigment epithelium (RPE) tears, macular holes, any retinal
             vasculopathy, vein occlusion, amblyopia, retinal inflammatory diseases, central serous
             choroidopathy, previous or existing retinal detachment, macular edema, anterior
             ischemic optic neuropathy, pseudovitelliform macular degeneration, vitreomacular
             traction syndrome, rhegmatogenous retinal detachment, generalized choroidal atrophy,
             and optic atrophy (pale));

          -  There is any history of vitreous hemorrhage three months before screening;

          -  The eye of interest has received any drug therapy for AMD (e.g., pegaptanib sodium or
             steroids) or any anti-VEGF therapy (e.g., ranibizumab or bevacizumab);

          -  The eye of interest has received verteporfin-photodynamic therapy (PDT) and foveal
             laser-induced thermal therapy (including subfoveal or paracentral photocoagulation,
             grid photocoagulation, transpupillary thermotherapy (TTT) and pan-retinal
             photocoagulation);

          -  The eye of interest has received intra- or periocular surgery (including parafoveal
             laser photocoagulation treatment, cataract surgery, and YAG laser posterior
             capsulotomy) within three months, except eyelid surgery having no effect on
             intravitreal injection (but eyelid surgery could not be performed one month before
             medication);

          -  The eye of interest has received the following ophthalmic operations, including
             vitrectomy, macular translocation, glaucoma surgery, laser photocoagulation and
             pan-retinal photocoagulation, as well as other submacular surgeries or other surgeries
             for CNV;

          -  The eye of interest has received keratoplasty;

          -  Either eye has active eye infection (e.g., blepharitis, infective conjunctivitis,
             keratitis, scleritis, and endophthalmitis) or recurrent infection, or the eye of
             interest has been infected 30 days before screening;

          -  Patient has either previous or existing uncontrollable glaucoma (defined as IOP
             remaining at above 25 mmHg after anti-glaucoma treatment), or the cup-to-disc ratio of
             the eye of interest is above 0.8 due to severe glaucoma, or the eye of interest has
             received glaucoma filtration surgery;

          -  No ruptured lens (excluding pseudophakic) or posterior lens capsule (except YAG laser
             posterior capsulotomy after intraocular lens implantation);

          -  Patient needs to receive cataract surgery three months after enrollment (i.e., the
             researcher judges that BCVA may decrease by no less than 10 alphabets for the subject
             if the surgery is not performed);

          -  The eye of interest has ocular tumor;

          -  There is a history of systemic use of anti-VEGF agent(s) in six months;

          -  Patient has a history of anaphylaxis and allergy to fluorescein sodium and indocyanine
             green, and of allergy to protein products for diagnosis or treatment, and is allergic
             to no less than two drugs and/or non-drug factors, or suffers from allergic diseases
             now;

          -  Diabetics with uncontrolled blood glucose (fasting blood glucose ≥ 7.0 mmol/L or 2hPBG
             ≥ 11.1 mmol/L) and/or complicated with diabetic retinopathy;

          -  Patient has had a surgical history one month before enrollment, and/or has unhealed
             wounds, ulcers and fractures at present;

          -  Patient has infectious diseases required oral, intramuscular or intravenous
             administration at present;

          -  Patient has a history of myocardial and/or cerebral infarction(s) within 6 months
             before screening, has received stenting and depends on such anticoagulants as warfarin
             and aspirin;

          -  Patient chronically uses and cannot discontinue to use such anticoagulants as aspirin,
             clopidogrel and warfarin;

          -  Patient has active and disseminated intravascular coagulation and distinct bleeding
             tendency three months before screening;

          -  Hyperpietics with poor blood pressure control (defined as blood pressure remaining at
             ≥ 150/95 mmHg after antihypertensives therapy);

          -  Patient is diagnosed with systemic immune disease (e.g., ankylosing spondylitis,
             systemic lupus erythematosus, and Behcet's disease) or has any uncontrollable clinical
             problem (e.g., AIDS, malignancies, active hepatitis, renal failure, severe mental,
             neurological, cardiovascular and respiratory diseases);

          -  Patient has previously used drugs which may possibly cause renal toxicity, including
             chloroquine, hydroxychloroquine, phenothiazines, chlorpromazine, thioridazine,
             fluphenazine, perphenazine, and trifluoperazine;

          -  Patient does not take effective contraceptive measures; Note: The following conditions
             are not included in the exclusion range.

               1. Amenorrhea for 12 months under the natural condition, or amenorrhea for 6 months
                  under the natural condition and the serum FSH level of &gt; 40 mIU/ml;

               2. Six weeks after bilateral ovariectomy with/without hysterectomy;

               3. Use of the following one or more acceptable contraceptions:

                    -  Sterilization (for males, with bilateral vasoligation and vasectomy)

                    -  Hormonal contraception (implantable, patchable, oral)

                    -  Intrauterine device and dural barrier method

               4. Ability to take reliable contraceptive measures over the study period and hold on
                  to 30 days after study drug withdrawal (unacceptable contraceptive methods
                  include: periodic continence - according to the calendar and ovulatory phase,
                  body thermometry, post-ovulatory method, and coitus interruptus).

          -  Pregnant women (in this trial pregnancy is defined as positive U-HCG) and
             breastfeeding mothers;

          -  Patient has participated in any drug (not including vitamins and minerals) clinical
             trial three months before screening (if the study drug has a long half-life, i.e., its
             five half-lives exceed three months, then it is deemed as five half-lives); Those whom
             the reseacher deems necessary to exclude.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiaoxin Li</last_name>
    <email>dr_lixiaoxin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Dai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hoospital.Cmu</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Xiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital,Cmu</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese Pla General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youxing Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People'S Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaoxin Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PEKING UNIVERSITY Third HOSPITAL</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongliang Dou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Scond Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luosheng Tang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huizuo Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospial og Guangzhou Military Command of PLA</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiulan Zou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZhongShan Ophthalmic Center,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenjin Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan Eye Hospital of Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Hainan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wangling Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei Eye Hospital</name>
      <address>
        <city>Hebei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minlian Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Hebei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingxue Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Province People's Hospital</name>
      <address>
        <city>Henan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guanfang Su</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenfang Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Eye Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingling Yi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiong Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengping Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital With Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinghui Lui</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningxia Peple'S Hospital</name>
      <address>
        <city>Ningxia</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoping Ha</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye&amp;Ent Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjing Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suqing Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stu/Cuhk Joint Shantou International Eye Center</name>
      <address>
        <city>Shantou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqi Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Eye Hospital</name>
      <address>
        <city>Shanxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yading Jia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Eye Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinshan Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Eye Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaorong Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eye Hospital of Wmu Zhejiang Eye Hospital</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoling Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiqiao Xing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Chinese people's liberation army 474 hospital</name>
      <address>
        <city>Wulumuqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Xiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiamen Eye Centre of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoji Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Yao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>July 16, 2017</last_update_submitted>
  <last_update_submitted_qc>July 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

